Literature DB >> 1335648

Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees.

R H Purcell1, E D'Hondt, R Bradbury, S U Emerson, S Govindarajan, L Binn.   

Abstract

Studies of active and passive immunoprophylaxis were carried out in chimpanzees to determine whether a candidate hepatitis A virus (HAV) vaccine could stimulate antibody to HAV (anti-HAV) that was qualitatively similar to anti-HAV stimulated by natural infection. Normal immune globulin (Ig) was prepared from plasma obtained from human volunteers before and after vaccination with the HAV vaccine, and these preparations or commercially prepared Ig were administered to chimpanzees. Protective efficacy was compared to that obtained after vaccination of chimpanzees. As expected, pre-vaccination Ig did not protect chimpanzees against challenge with virulent hepatitis A. In contrast, chimpanzees were protected against hepatitis A by Ig prepared from volunteers who had received hepatitis A vaccine. The protection was qualitatively similar to that afforded by commercial normal Ig containing convalescent anti-HAV. The minimum protective dose of passively acquired anti-HAV was approximately the minimum dose detectable by serological means. This information will be useful in calculating minimum acceptable titres of anti-HAV in normal Ig. Whereas administration of Ig protected chimpanzees against hepatitis A pathology, it did not protect them from infection with HAV. Thus, these chimpanzees were protected by classical passive-active immunoprophylaxis. In contrast, chimpanzees actively immunized with HAV vaccine were apparently protected against both hepatitis A pathology and HAV infection. The mechanism of this complete protection is unknown but may simply represent the higher titre of anti-HAV in the vaccinated chimpanzees, compared to the passively protected animals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335648     DOI: 10.1016/0264-410x(92)90572-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Protecting travellers from hepatitis A.

Authors:  G Webster; E Barnes; G Dusheiko; I Franklin
Journal:  BMJ       Date:  2001-05-19

2.  In Memoriam: Robert M. Chanock, MD, 1924–2010.

Authors:  Albert Z Kapikian; David M Morens; Anthony S Fauci
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

Review 3.  Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections.

Authors:  Christopher M Walker
Journal:  Cold Spring Harb Perspect Med       Date:  2019-09-03       Impact factor: 6.915

Review 4.  The History of Hepatitis A.

Authors:  Daniel Shouval
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-10-07

5.  Chimpanzees as an animal model for human norovirus infection and vaccine development.

Authors:  Karin Bok; Gabriel I Parra; Tanaji Mitra; Eugenio Abente; Charlene K Shaver; Denali Boon; Ronald Engle; Claro Yu; Albert Z Kapikian; Stanislav V Sosnovtsev; Robert H Purcell; Kim Y Green
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

Review 6.  Nonhuman Primate Models of Hepatitis A Virus and Hepatitis E Virus Infections.

Authors:  Robert E Lanford; Christopher M Walker; Stanley M Lemon
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

Review 7.  Immunization against Hepatitis A.

Authors:  Daniel Shouval
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

8.  Successful passive and active immunization of cynomolgus monkeys against hepatitis E.

Authors:  S A Tsarev; T S Tsareva; S U Emerson; S Govindarajan; M Shapiro; J L Gerin; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

9.  Successful Vaccines.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Curr Top Microbiol Immunol       Date:  2018-07-26       Impact factor: 4.291

10.  Studies on transmission of hepatitis A virus to squirrel monkeys.

Authors:  Cláudia L Vitral; Clara F T Yoshida; Renato S Marchevsky; Marcelo A Pinto; Cristiane S Teixeira; Márcia L Baptista; Ana Maria C Gaspar
Journal:  Primates       Date:  2000-04       Impact factor: 1.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.